Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 30;40(32):4303-4306.
doi: 10.1016/j.vaccine.2022.05.086. Epub 2022 Jun 6.

Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak

Rabeh El-Shesheny  1 , Ahmed El Taweel  2 , Mokhtar R Gomaa  3 , Wael H Roshdy  4 , Ahmed Kandeil  5 , Richard J Webby  6 , Ghazi Kayali  7 , Mohamed A Ali  8
Affiliations

Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak

Rabeh El-Shesheny et al. Vaccine. .

Abstract

The diversity of SARS-CoV-2 continues to lead to the emergence of new SARS-CoV-2 variants. SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic by determining the neutralizing antibody response. This study aims to investigate vaccine-induced antibodies against most common variants of SARS-CoV-2 in Egypt. Sera samples were collected from vaccinated participants and neutralizing activity against the SARS-CoV-2 variants was determined using microneutralization assay. Our results show that the BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCov-19 (AstraZeneca), and Ad26.COV2.S COVID-19 (Janssen) vaccines elicited neutralizing antibody responses more than the BBIBP-CorV vaccine (Sinopharm) against B.1, C.36.3, and AY.32 (Delta) variants. While vaccines remain highly effective in managing the COVID-19 pandemic, ongoing monitoring of vaccine effectiveness is needed.

Keywords: COVID-19 pandemic; Microneutralization assay; Neutralizing antibodies; SARS-CoV-2; SARS-CoV-2 vaccine; Vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Neutralizing antibody responses against the B.1, C36.3, and AY.32 Delta variants.
Fig. 2
Fig. 2
Antibody response elicited by SARS-CoV-2 vaccines.
See this image and copyright information in PMC

References

    1. Edara V.V., Hudson W.H., Xie X., Ahmed R., Suthar M.S. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA. 2021;325(18):1896. doi: 10.1001/jama.2021.4388. - DOI - PMC - PubMed
    1. Naaber P., Tserel L., Kangro K., Sepp E., Jürjenson V., Adamson A., et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208. doi: 10.1016/j.lanepe.2021.100208. - DOI - PMC - PubMed
    1. WHO. WHO Coronavirus (COVID-19) Dashboard; 2022. <https://covid19.who.int/>.
    1. McGill, COVID19 Vaccine Tracker Team. Egypt-COVID19 Vaccine Tracker; 2022. <https://covid19.trackvaccines.org/country/egypt/>.
    1. Gomaa M.R., El Rifay A.S., Shehata M., Kandeil A., Nabil Kamel M., Marouf M.A., et al. Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: results of a community-based cohort. PLoS Pathog. 2021;17(3):e1009413. doi: 10.1371/journal.ppat.1009413. - DOI - PMC - PubMed

Publication types

Supplementary concepts